T he Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2), a phase 3 randomized clinical trial, was conducted to investigate whether bevacizumab, a treatment commonly used off-label, is noninferior to aflibercept, a treatment approved by the US Food and Drug Administration, with respect to visual acuity (VA) in eyes with macular edema (ME) associated with central retinal vein occlusion (CRVO) or hemiretinal vein occlusion (HRVO). 1 Between September 2014 and November 2015, 304 patients with CRVO and 58 patients with HRVO were enrolled at 66 private practice or academic centers in the United States and randomly assigned to receive intravitreal injection of bevacizumab, 1.25 mg, or aflibercept, 2.0 mg, at randomization and every 4 weeks through month 5. The primary outcome was change from baseline in best-corrected electronic Early Treatment Diabetic Retinopathy Study (e-ETDRS) VA letter score (VALS) at month 6, with a noninferiority margin of 5. At month 6, bevacizumab was noninferior to aflibercept (mean VALS improvement from baseline, 18.6 vs 18.9; noninferiority P = .001, lower 1-tailed 97.5% CI = −3.1 to infinity). Central subfield thickness (CST) measured with spectral domain optical coherence tomography (SD-OCT) decreased significantly through month 6 in both arms, with a higher proportion of aflibercept-treated eyes achieving resolution of ME than bevacizumab-treated eyes (54% vs 29%, P < .001). 1 There were no differences in the adverse event profile between the 2 arms. The purpose of the current report is to investigate baseline factors associated with month 6 VA and SD-OCT outcomes in patients with ME secondary to CRVO or HRVO in SCORE2.
Methods
The SCORE2 design and methods have been described in detail 2 and are summarized here. The study adhered to the tenets of the Declaration of Helsinki. 3 Institutional review board approval of the protocol was obtained from either a site-specific or centralized institutional review board, and written informed consent was obtained from all participants before eligibility screening and again before randomization into the study. Institutional review board approval is not required for each subsequent analysis. Stratification at randomization oc- 
Study Population
The analyses included 348 participants (96%) with a 6-month VALS measurement and 335 participants (93%) with gradable 6-month SD-OCT images of the 362 SCORE2 participants. The mean (SD) age of SCORE2 participants was 69 (12) years, with 43% women, 76% white, and 15% black. The mean VALS was 50 (approximate Snellen 20/100; VALS range, 19-73) and participants had ME for an average of 7 months (range, 0-104 months) before randomization. The mean CST was 666 μm (range, 219 μm-1420 μm), 33% had received anti-vascular endothelial growth factor (VEGF) treatment prior to study participation, 8% had prior intravitreal steroid treatment, and 16% were diagnosed as having HRVO.
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Testing and Treatment Protocol
Study visits were scheduled every 4 weeks for 6 months. At each study follow-up visit, both eyes had VA assessed by the e-ETDRS method, 4 intraocular pressure measurement, and slitlamp and dilated funduscopic examinations. Spectral domain OCT images were obtained monthly. At the reading center, OCT scans were converted to DICOM format, allowing graders to view and analyze scans in a custom software program. This grading method is independent of the OCT device, minimizing the measurement incongruity between different OCT manufacturers. Central subfield thickness values presented in this article are based on grading from the reading center. Resolution of ME was defined as CST less than 300 μm, no subretinal or intraretinal fluid, and no cystoid spaces within the ETDRS grid based on reading center evaluation. Stereoscopic fundus photographs taken at baseline and month 6 were analyzed for area of retinal hemorrhage and the presence or absence of other CRVO features such as retinal neovascularization, macular atrophy, and macular pigment. At selected sites, ultra-widefield fluorescein angiograms were obtained at baseline and month 6 to evaluate for retinal nonperfusion and vascular leakage. Study participants were masked to treatment assignment through month 6. At month 6, VA examiners and SD-OCT technicians were masked to treatment assignments.
Statistical Analysis
The primary goal of this article is to identify baseline characteristics of the SCORE2 population associated with VA and SD-OCT outcomes at month 6. For VA, 2 outcomes were investigated: mean change from baseline in best-corrected VALS (ie, the baseline score subtracted from the month 6 score) and a VALS gain from baseline of 15 or greater. Baseline factors associated with a VALS loss of 15 or greater from baseline were not analyzed because less than 2% of SCORE2 participants experienced this visual loss outcome at month 6. Three SD-OCT outcomes were evaluated based on reading center grading: mean change from baseline in CST (ie, the baseline CST subtracted from the CST at month 6), a 6-month CST measurement of less than 300 μm, and resolution of ME at month 6. For the binary outcomes in the analyses (eg, a VALS gain from baseline of ≥15), the log odds of the outcome were modeled as a linear function of the baseline variable using logistic regression to determine whether the baseline factors in question were important. For continuous outcomes (eg, change from baseline in VALS), a standard linear regression was performed, again investigating whether the baseline factors were important.
The statistical tests of the univariate relationships between these baseline factors and the 5 outcome variables at the 6-month follow-up visit resulted in 140 P values. Nominal P values were used as a "filter" with which to control the number of baseline variables later included in multivariate analyses. To control for type 1 error, the familywide error of the multivariate tests was set at 5% using the Hochberg 5 sequentially rejective method. A baseline factor was considered significant if its Hochberg-adjusted multivariate P value was less than .05 (2-sided).
Results Table 1 displays univariate analyses uncorrected for multiple testing of baseline factors associated with VALS at month 6, which are consistent across the 2 VA outcomes. Younger age, lower baseline VALS, shorter duration between diagnosis of ME and randomization, a natural lens, no prior anti-VEGF treatment, no prior steroid treatment, and larger baseline CST were all associated with better VA outcomes at month 6 based on higher odds of a VALS gain of 15 or more and greater positive mean changes from baseline in VALS at month 6. A larger baseline CST was associated with positive (beneficial) changes for odds of a VALS gain of 15 or greater and mean change from baseline in VALS at month 6. However, compared with bevacizumab, aflibercept treatment was not associated with a better VA outcome. Further, no other demographic, clinical, or study eye variables were identified as associated with VA at month 6. Table 2 summarizes the univariate analyses for baseline associations with SD-OCT outcomes in study participants. There were many nominally significant factors associated with SD-OCT outcomes from these unadjusted analyses, and described here are only those variables that are statistically significant on 2 or more SD-OCT outcomes. Randomization assignment of aflibercept, relative to bevacizumab, was associated with positive (beneficial) SD-OCT changes at month 6, with higher odds of ME resolution and CST of less than 300 μm. Eyes with a natural lens, relative to a prior lens extraction at baseline, had better SD-OCT outcomes, with higher odds of ME resolution and a larger CST reduction from baseline. Shorter duration between diagnosis of ME and randomization also had a positive impact on SD-OCT outcomes, with higher odds of ME resolution and a larger reduction from baseline in CST than those with a longer duration of ME. Last, the presence of subretinal fluid as identified on the SD-OCT by the reading center was associated with positive outcomes based on higher odds of CST less than 300 μm and greater mean reduction from baseline in CST.
The multivariate analyses showing the results only for baseline factors that were statistically significant with an adjusted P value less than .05 based on the Hochberg 5 method were consistent across the 2 VA outcomes ( Table 3) . Both younger age and lower (worse) baseline VALS were associated with greater odds of a VALS gain of 15 or more and a greater mean increase from baseline in VALS. More specifically, the estimated odds ratio for VALS gain of 15 or greater is multiplied by 1/0.95 = 1.05 for every 1-year decrease in age (P = .007) and by 1/0.96 = 1.04 for every 1-unit decrease in baseline VALS (P < .001). Also, estimated mean VALS change from baseline increases by 0.27 for every year of decrease in age (P = .006) and by 0.38 for every unit of decrease in baseline VALS (P < .001).
For the CST outcomes, many of the nominally significant univariate variables were no longer significant in the multivariate model after adjusting for multiple comparisons ( Table 4) . Randomization to aflibercept treatment, compared with bevacizumab, remained significant, with aflibercept treatment having higher odds of ME resolution (odds ratio, 3.59; 95% CI, 2.22-5.80; P < .001) and higher odds of CST less than 300 μm (odds ratio, 5.30; 95% CI, 2.40-11.67; P = .001). Study eyes that were anti-VEGF naive at baseline had odds for resolution of ME that were 1/0.33 = 3 times greater than eyes with prior anti-VEGF treatment (P = .03). Further, higher baseline CST was associated with a greater decrease in CST from baseline to month 6 (ie, a mean decrease of 79 μm in CST for every 100 μm in CST at baseline; P = .002) and higher baseline VALS was associated with less of a decrease in CST from baseline to month 6 (ie, the decrease was approximately 4 μm less in CST for every 1-letter increase in VALS at baseline; P = .04).
Discussion
This analysis was conducted to identify baseline factors associated with VA and SD-OCT outcomes in patients treated with intravitreal anti-VEGF therapy for ME due to CRVO or HRVO in SCORE2.
In the multivariate analyses, younger age and lower baseline VALS were associated with better VA outcomes as assessed by VALS gain of 15 or greater and an increase from baseline in VALS. Age was also identified in the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE)-CRVO Trial (which compared intravitreal triamcinolone with observation for ME secondary to CRVO) as a significant baseline factor of 6-month VA outcomes, with younger age associated with a gain of 15 or greater in VALS. 6 As hypothesized when discussing the SCORE Study findings, 6 this may be the result of an enhanced resilience of younger patients' photoreceptors that may permit the retina to recover after an acute insult such as RVO compared with photoreceptors of older patients. Among patients treated with grid photocoagulation for ME in the Central Vein Occlusion Study, VA outcome tended to be better for younger patients, although this interaction between treatment effect and age was not statistically significant, perhaps due to the limited sample size. 7 As is the case in SCORE2, the COPERNICUS Study 8 (a randomized trial that compared intravitreal aflibercept with sham injections for CRVO-associated ME) also found that a lower baseline VALS was associated with greater improvement from baseline in VALS; this is most likely due to a ceiling effect (ie, starting from a higher baseline VALS leaves less room for VA improvement with anti-VEGF therapy than starting from a lower baseline VALS). With anti-VEGF treatment of diabetic ME, younger age and worse baseline VA have also been shown to be associated with greater VA improvement, and greater baseline retinal thickening has been shown to be associated with greater reduction in retinal thickening.
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This suggests similarities between treatment response of eyes with ME from diabetes and CRVO and HRVO. Multivariate analyses identified the following baseline factors associated with favorable SD-OCT outcomes: aflibercept treatment, no prior anti-VEGF treatment, and higher baseline CST. In SCORE2, randomization to aflibercept (compared with bevacizumab) was associated with higher odds of ME resolution and higher odds of CST less than 300 μm. These month 6 findings are consistent with results of Diabetic Retinopathy Clinical Research Network Protocol T, in which aflibercept was more effective at reducing retinal thickness than bevacizumab at 1 year and at 2 years in eyes with diabetic ME.
9,10 The greater effectiveness of aflibercept relative to bevacizumab in reducing retinal thickness may be due to aflibercept's broader mechanism of action and/or tighter binding affinity. While aflibercept and bevacizumab inhibit all isoforms of VEGF-A, aflibercept also inhibits VEGF-B and placental growth factor.
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In addition to its broader mechanism of action, aflibercept has been reported to have a higher binding affinity to VEGF-A than bevacizumab. 13, 14 In SCORE2, eyes with prior anti-VEGF treatment at baseline, compared with anti-VEGF-naive study eyes, had lower odds of ME resolution. This finding may be explained by anti-VEGF treatment prior to randomization signifying worse disease, which has already been refractory to anti-VEGF therapy and which, therefore, may be more likely to be refractory to additional anti-VEGF treatment. Higher baseline CST was predictive of a larger reduction from baseline in CST compared with a lower baseline CST. This may be because anti-VEGF therapy is, in general, quite effective in reducing ME and eyes with a higher baseline CST have a greater potential CST reduction than eyes with a lower baseline CST. Similar to SCORE2, in the SCORE Study, a higher baseline central retinal thickness was also associated with a greater reduction in central retinal thickness. 6 There needs to be caution when interpreting a variable whose baseline value is part of the calculation of the outcome because this relationship is affected by "part-whole correlation." 15 For example, the negative correlation between baseline CST and change in CST from baseline to month 6 may be because, to calculate the 6-month change, the baseline value is subtracted from the month 6 thickness. Finally, note that a few of the outcomes in Table 4 could be at least partially the result of regression to the mean. For example, one inclusion criterion for SCORE2 is a baseline CST of 300 μm or greater. Because of measurement error, some participants with true CST less than 300 μm may have been accidentally included. Even if the participants' true CST did not change, these participants will appear improved at 6 months. A similar argument applies to the effect of baseline VALS on VA outcomes. In univariate analyses of SCORE2 data, shorter duration between diagnosis of ME and randomization was associated with higher odds of a VALS gain of 15 or greater, a larger improvement from baseline in VALS at month 6, higher odds of ME resolution, and a greater reduction in CST from baseline. This is consistent with findings in both of the previously reported randomized trials, which compared intravitreal aflibercept with sham injections for CRVO-associated ME (the COPERNICUS 8 and GALILEO 16 studies), in which time since diagnosis of CRVO of 2 months or less was associated with better VA outcomes than time since CRVO diagnosis of greater than 2 months. Similarly, in the SCORE Study, shorter duration of ME was associated with a greater reduction from baseline in OCT-measured center point thickness. 6 One may hypothesize that retinal anatomic changes of shorter duration are more likely to be reversible compared with more chronic changes in retinal architecture. However, in multivariate models analyzing SCORE2 data after adjustment for multiple testing, duration between diagnosis of ME and randomization was not identified as significantly associated with VALS or SD-OCT outcomes. In SCORE2, systemic factors investigated were not associated with either VALS or SD-OCT outcomes. While history of coronary artery disease may be a marker for more underlying systemic ischemia, which may be hypothesized to portend a graver VA and anatomic prognosis after CRVO, history of coronary artery disease was not found to be an important baseline factor in the SCORE-CRVO trial 6 or SCORE2, perhaps because patients judged by the investigator to have an ischemic CRVO were excluded from these trials. Although hypertension is a well-reported risk factor for the development of an RVO, 17-25 a history of hypertension was not significantly associated with outcome in either SCORE2 or the SCORE Study. 6 As hypothesized previously, 6 this may be due, at least in part, to the fact that patients with a history of hypertension (which was assessed in SCORE2 and in the SCORE Study based on patient self-report) were aware of their diagnosis and, thus, were likely being treated for hypertension. The association between undiagnosed, untreated, or poorly controlled hypertension and outcome in patients with RVO is unknown.
Limitations
Extrapolating results from clinical trials to clinical practice should be made with caution. For example, the findings reported in this article need to be interpreted in light of excellent adherence, with approximately 90% of participants receiving 6 monthly anti-VEGF injections. There are also caveats that should be considered with cross-trial comparisons. For example, this analysis focuses on 6-month outcomes (which is consistent with the primary outcome time point in the previously reported phase 3 studies of aflibercept for CRVOassociated ME [the Copernicus 8 and Galileo 16 studies]) while the primary outcome time point in the SCORE Study was at 1 year. 26 Timing of measuring outcome may influence the identification of baseline factors based on short-term vs longerterm impact of treatment.
Conclusions
The SCORE2 Study identified a number of baseline factors associated with 6-month outcomes. Consistent with other studies, younger age and worse baseline VA are consistently associated with greater improvement in VA at month 6. Compared with bevacizumab, aflibercept treatment was associated with better SD-OCT outcomes of CST less than 300 μm and resolution of ME but not VA outcomes. These findings may assist clinicians in assessing response to treatment over a 6-month period for patients with ME secondary to CRVO or HRVO who receive monthly anti-VEGF treatment, but they do not change the conclusions of the primary outcome results that bevacizumab was noninferior to aflibercept for mean VA improvement at 6 months. of intravitreous anti-vascular endothelial growth factor (VEGF) therapy for improving visual acuity with CRVO. However, it has been largely unclear which, if any, of the available anti-VEGF agents provides the best functional or anatomic outcomes. Given substantial differences in cost and availability between anti-VEGF drugs, a rigorous comparison of efficacy and safety among the most widely used agents has major implications for both individual patient treatment decisions and public health policy.
To address this issue, the Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2) trial, through funding from the National Eye Institute, randomly assigned patients with macular edema from CRVO or hemi-RVO to monthly treatment with either aflibercept or bevacizumab. The primary results from this study are reported in JAMA. 1 At 6 months, the primary outcome of mean visual acuity letter score improvement from baseline was similar in the 2 groups among 362 study participants: 18.9 in the aflibercept group and 18.6 in the bevacizumab group (equivalent to a mean improvement of slightly less than 4 Snellen lines in each group). The lower bound of the confidence interval for the treatment group difference was less than the prespecified noninferiority margin of 5 letters. Thus, one can conclude from these results that average visual acuity outcomes at 6 months are not worse in eyes treated with bevacizumab compared with aflibercept for macular edema from CRVO. The proportions of eyes with 15 or more letter visual acuity gain were similar between the treatment groups (aflibercept, 65% vs bevacizumab, 61%), as were the percentages of eyes that achieved visual acuity of approximately 20/40 or better (aflibercept, 58% vs bevacizumab, 57%). Interestingly, although the visual outcomes were equivalent between aflibercept-and bevacizumab-treated eyes, retinal thickness outcomes were better with aflibercept, with more eyes attaining resolution of macular edema after treatment with aflibercept as compared with bevacizumab (54% vs 29%). No major differences were found in ocular or systemic adverse events between the treatment groups.
The SCORE2 report is encouraging in that it suggests that the lower cost and presumably most globally used anti-VEGF agent, bevacizumab, can be used to provide similar visual acuity gains to those obtained with aflibercept through at least 6 months in eyes with macular edema from CRVO. It should be noted that bevacizumab is not approved for this indication by the US Food and Drug Administration. Furthermore, there are clinical questions that remain after the SCORE2 primary results. These include whether alternate dosing regimens or use of commercially available repackaged or compounded bevacizumab will impact patient outcomes and whether these findings will generalize to eyes with branch RVO. Also critical is the question of whether equivalent visual acuity results in the bevacizumab vs aflibercept groups at 6 months will be maintained as patients continue in their randomized treatment assignments over longer-term follow-up. The fact that eyes in the SCORE2 bevacizumab group were more likely to have persistent macular edema at 6 months suggests the possibility that there could be worse visual outcomes in the bevacizumab vs the aflibercept group as these eyes are followed up for a longer period.
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